Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: The example of Alzheimer's disease

Annales Pharmaceutiques Francaises

Volumn 71, Issue 4, 2013, Pages 225-233

  Andrieux, K ^a   Couvreur, P ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Alzheimer; Brain diseases; Diagnosis; Nanomedicine; Nanoparticles; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; CURCUMIN; GALANTAMINE; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3; INSULINASE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; METALLOPROTEINASE; MICROTUBULE ASSOCIATED PROTEIN; RIVASTIGMINE; TAU PROTEIN; TRANSFERRIN RECEPTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN WEIGHT; CEREBROSPINAL FLUID; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; EARLY DIAGNOSIS; ENCAPSULATION; EXOCYTOSIS; FRONTAL CORTEX; HUMAN; IN VITRO STUDY; MILD COGNITIVE IMPAIRMENT; MONONUCLEAR PHAGOCYTE; NANOMEDICINE; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; PARIETAL LOBE; PEPTIDE SYNTHESIS; PH; SHORT SURVEY; TEMPORAL LOBE; TIGHT JUNCTION;

ALZHEIMER; BRAIN DISEASES; DIAGNOSIS; DIAGNOSTIC; MALADIES CÉRÉBRALES; NANOMÉDECINE; NANOMEDICINE; NANOPARTICLES; NANOPARTICULES; TRAITEMENT; TREATMENT;

ALZHEIMER DISEASE; BRAIN DISEASES; HUMANS; NANOMEDICINE; NANOPARTICLES;

EID: 84880036112     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2013.04.001     Document Type: Short Survey

References (36)

1. Ferreira P.C., Piai Kde A., Takayanagui A.M., Segura-Muñoz S.I. Aluminum as a risk factor for Alzheimer's disease. Rev Lat Am Enfermagem 2008, 16:151-157.
2. Findeis M.A. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 2007, 116:266-286.
3. Re F., Airoldi C., Zona C., Masserini M., La Ferla B., Quattrocchi N., et al. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Curr Med Chem 2010, 17:2990-3006.
4. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
5. Plant L.D., Boyle J.P., Smith I.F., Peers C., Pearson H.A. The production of amyloid peptide is a critical requirement for the viability of central neurons. J Neurosci 2003, 23:5531-5535.
6. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., et al. Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499.
7. Herz J. LRP: a bright beacon at the blood-brain barrier. J Clin Invest 2003, 112:1483-1485.
8. Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 2004, 43:605-608.
9. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66:137-147.
10. Feldman H.H., Ferris S., Winblad B., Sfikas N., Mancione L., He Y., et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007, 6:501-512.
11. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, 2:CD003154.
12. De Kimpe L., Scheper W. From alpha to omega with abeta: targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease. Curr Med Chem 2010, 17:198-202.
13. Lowe T.L., Strzelec A., Kiessling L.L., Murphy R.M. Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLFVV. Biochemistry 2001, 40:7882-7889.
14. Austen B.M., Paleologou K.E., Ali S.A.E., Qureshi M.M., Allsop D., El-Agnaf O.M.A. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's β-amyloid peptide. Biochemistry 2008, 47:1984-1992.
15. Couvreur P., Gref R., Andrieux K., Malvy C. Nanotechnologies for drug delivery: application to cancer and autoimmune diseases. Progr Solid State Chem 2006, 34:231-235.
16. Andrieux K., Desmaële D., D'Angelo J., Couvreur P. Nanotechnologies et nouveaux médicaments. Actu Chim 2003, 135-139.
17. Peracchia M.T., Harnisch S., Pinto-Alphandary H., Gulik A., Dedieu J.C., Desmaele D., et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 1999, 20:1269-1275.
18. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int J Pharm 2005, 298:274-292.
19. Calvo P., Gouritin B., Chacun H., Desmaële D., d'Angelo J., Noël J.P., et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001, 18:1157-1166.
20. Kim H.R., Gil S., Andrieux K., Nicolas V., Appel M., Chacun H., et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 2007, 64:356-364.
21. Kim H.R., Andrieux K., Gil S., Taverna M., Chacun H., Desmaële D., et al. Translocation of poly(ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007, 8:793-799.
22. Nicolas J., Brambilla D., Carion O., Pons T., Maksimovic I., Larquet E., et al. Quantum dots-loaded pegylated poly(alkyl cyanoacrylate) nanoparticles for in vitro and in vivo imaging. Soft Matter 2011, 7:6187-6193.
23. Karatas H., Aktas Y., Gursoy-Ozdemir Y., Bodur E., Yemisci M., Caban S., et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 2009, 29:13761-13769.
24. Wilson B., Samanta M.K., Santhi K., Kumar K.P., Paramakrishnan N., Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008, 1200:159-168.
25. Mulik R.S., Monkkonen J., Juvonen R.O., Mahadik K.R., Paradkar A.R. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm 2010, 7:815-825.
26. Cabaleiro-Lago C., Quinlan-Pluck F., Lynch I., Lindman S., Minogue A.M., Thulin E., et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc 2008, 130:15437-15443.
27. Brambilla D., Verpillot R., Taverna M., De Kimpe L., Le Droumaguet B., Nicolas J., et al. New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide. Anal Chem 2010, 15:10083-10089.
28. Brambilla D., Verpillot R., Le Droumaguet B., Nicolas J., Taverna M., Kóňa J., et al. Pegylated nanoparticles bind to and alter amyloid-beta peptide conformation: towards engineering of functional nanomedicines for Alzheimer's disease. ACS Nano 2012, 6:5897-5908.
29. Brambilla D., Souguir H., Nicolas J., Mackiewicz N., Verpillot R., Le Droumaguet B., et al. Colloidal properties of biodegradable nanoparticles influence interaction with amyloid-Beta peptide. J Biotechnol 2010, 156:338-340.
30. Le Droumaguet B., Nicolas J., Brambilla D., Mura S., Maksimenko A., De Kimpe L., et al. Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano 2012, 6:5866-5879.
31. Yang J., Zaim Wadghiri Y., Minh Hoang D., Tsui W., Sun Y., Chung E., et al. Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. NeuroImage 2011, 55:1600-1609.
32. Roney C.A., Arora V., Kulkarni P.V., Antich P.P., Bonte F.J. Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer's disease. Int J Alzheimer Dis 2009, 2009:481031-481039.
33. Keating C.D. Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc Natl Acad Sci U S A 2005, 102:2263-2264.
34. Neely A., Perry C., Varisli B., Singh A.K., Arbneshi T., Senapati D., et al. Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon rayleigh scattering properties of gold nanoparticle. ACS Nano 2009, 3:2834-2840.
35. Tokuraku K., Marquardt M., Ikezu T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS One 2009, 4:e8492.
36. Xu G., Yong K.T., Roy I., Mahajan S.D., Ding H., Schwartz S.A., et al. Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem 2008, 19:1179-1185.